KDM6B and neoplasm: The clinical data, coupled with increased peripheral antigen-presenting cells and reduction in KDM6B expressing immune-suppressive myeloid cell subsets in patients who underwent surgical removal of the tumor provided the potential mechanistic insight into immune modulation following cytoreductive surgery in a metastatic setting.